Download Map It - CanBiotech

Atlas Venture, Inc.
Address:
890 Winter Street Suite 320
Waltham, MA 02451
UNITED STATES
Map It
Contact Info:
T: (781) 622-1700
F: (781) 622-1701
E: [email protected]
Website URL:
www.atlasventure.com/
Other Locations
1201 Third Avenue
Suite 5450
Seattle, WA 98101, USA
t: +1 206 694 8600
f: +1 206 254 9130
e: [email protected]
Go Back
About Us
Atlas Venture is the leading international early-stage venture
capital firm, investing in communications, information
technology and life sciences companies. Atlas Venture has
investing offices in Boston, London, Menlo Park, Munich, Paris
and Seattle, and its investments are evenly divided between
the United States and Europe.
Founded in 1980, Atlas Venture has organized six
international funds, and currently manages more than $2.4
billion in committed capital.
The Life Sciences investment team offers portfolio companies
expertise in biotechnology licensing and marketing, business
management, and medical practice.
Preferred Stage
Many of Atlas Venture’s Life Sciences portfolio companies are
developing new platform technologies to leverage the data
generated from the human genome project and enhance the
drug discovery process. Others are developing new medical
devices, or using the Internet to streamline drug
development and healthcare delivery.
Geographic Focus
With more than twenty years in international venture
investing, the Atlas Venture team has developed a vast
international network of business contacts to help portfolio
companies make connections quickly. With offices and local
contacts in major American and European markets, can
provide practical assistance to companies expanding
operations to other countries.
Capital
More than $2.4 billion in committed capital
Investment Portfolio
Acambis Plc, Achillion Pharmaceuticals, Inc, Actelion
Pharmaceuticals Ltd, Akceli, Inc, Allelix Biopharmaceuticals
Inc, Alnylam Pharmaceuticals, Inc., Anadys Pharmaceuticals,
Archemix Corp, ArQule, Inc, Artemis Pharmaceuticals GmbH,
Aureon Biosciences, Axovan Ltd., Boston Medical
Technologies, Inc CellZome GmbH, Ciphergen Biosystems,
Inc, CropDesign NV, Crucell NV, deCODE genetics, Inc,
DeveloGen AG, EntoMed SA, Exelixis, Inc, Hexagen Plc,
Immuno-Designed Molecules SA, IsoTis NV, Kriton Medical,
MediGene AG, Microcide, Inc, Micromet AG, Modex
Therapeutiques SA, MorphoSys AG, Neurochem, Inc,
Neurotech SA, Newron Pharmaceuticals, Novuspharma
S.p.A., NxStage Medical, Oxford GlycoSciences Plc, Percardia
Inc, Prolifix Ltd, Renovo, Ltd, Signature BioScience, Inc,
Structural GenomiX, Inc, Transfusion Technologies, Inc,
Variagenics, Inc, Vasca, Inc
Investor Cross Search
Click on the company name to see other investors in the
company.
Acambis, Achillion Pharmaceuticals, Actelion Pharmaceuticals,
Akceli, Allelix Biopharmaceuticals, Alnylam Pharmaceuticals,
Anadys Pharmaceuticals, Archemix, ArQule, Artemis
Pharmaceuticals, Aureon Biosciences, Axovan, Boston Medical
Technologies, CellZome, Ciphergen Biosystems, CropDesign,
Crucell deCODE genetics DeveloGen EntoMed Exelixis
Hexagen, Immuno-Designed Molecules, IsoTis, Kriton
Medical, MediGene, Microcide, Micromet, Modex
Therapeutiques, MorphoSys, Neurochem, Neurotech, Newron
Pharmaceuticals, Novuspharma, NxStage Medical, Oxford
GlycoSciences, Percardia, Prolifix, Renovo, Signature
BioScience, Structural GenomiX, Transfusion Technologies,
Variagenics, Vasca